Sign in
CompletedNo phase

A Digital Cognitive Behavioural Therapy for Insomnia Intervention in Mild Cognitive Impairment and Mild Dementia

Key facts

Who runs it
University College Cork
Where
Ireland1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
30 people enrolled
Started
1 Jan 2025
Ended
30 Sept 2025
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Digital cognitive behavioural therapy for insomnia
Record updated
23 January 2026

Who can take part

Age
50 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Age ≥50 years
  • Sleep Condition Indicator Score ≤16/32
  • Established Mild Cognitive Impairment (MCI) or mild dementia, diagnosed by a consultant physician specialised in cognitive disorders prior to enrolment in the study. Dementia will be defined using DSM-5 classification and staged according to the Reisberg FAST scale into early/mild stage (Stages 1-4). MCI will be defined using Petersen's criteria. To participate those with MCI/mild dementia must score:; ≥18 on the Mini-Mental State Examination (MMSE), and; ≥0.5-1.0 on the Clinical Dementia Rating (CDR) scale
  • Internet access for the duration of the intervention (via computer/tablet/smartphone)
  • Sufficient physical/sensory (visual/hearing) capacity to use the intervention, as judged by the clinician/investigator
  • English-speaker (intervention only available in English)
  • Community-dwellers (non-institutionalised)

Who cannot take part

  • Receipt of a sleep-related cognitive behavioural therapy (CBT) intervention within the past six months
  • Planned surgery or hospitalisation during the study that could interfere with participation
  • A change in the following medication within the three months prior to enrolment:; Benzodiazepine and non-benzodiazepine hypnotic or anxiolytics agents; Cholinesterase inhibitors or Memantine; Antidepressants; Antipsychotics; Amphetamine derivatives; Decongestants (pseudoephedrine, phenylephrine, phenyl¬propanolamine); Narcotic analgesics; β-Blockers; Pulmonary medications (theophylline and albuterol); Melatonin
  • Known history of an International Classification of Diseases (ICD) defined sleep disorder other than insomnia disorder
  • MMSE score <18 at enrolment, to facilitate adherence and ensure recruitment of those with mild-stage disease
  • Unstable depression/anxiety disorders or panic attacks (unstable will be defined as changes in antidepressant medications within the last 3 months, i.e. no start, stop or change in dose)
  • Other relevant major neuropsychiatric disorders, including schizophrenia, psychosis, mania, bipolar affective disorder, epilepsy or seizure disorder
  • Long-term physical or sensory impairment, pain or other medical condition which, in the opinion of the principal investigator, could impair participation for reasons other than cognitive impairment
  • Medical conditions rendering the patient too unwell to continue to participate in the study in the opinion of the principal investigator
  • Severe depression (defined as depression requiring hospitalisation in the past 12-months or visit to psychiatry outpatient clinic in the past 3 months)
  • Ongoing substance or alcohol abuse

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to assess the feasibility of conducting a definitive randomised controlled trial that will determine the effectiveness of a digital cognitive behavioural therapy for insomnia intervention (Sleepio) in improving sleep, psychosocial health and cognitive performance in people with Mild Cognitive Impairment or mild dementia and co-morbid sleep disturbance.

The 2 groups in the trial

  • Intervention GroupTreatment being tested

    Participants allocated to the intervention group will be provided with access to Sleepio, a fully-automated digital cognitive behavioural therapy for insomnia programme designed to treat insomnia using a combination of evidence-based cognitive and behavioural techniques. Underlying algorithms organise the delivery of information, support, and advice in a manner tailored to each individual participant based on their responses to an initial sleep study questionnaire and subsequent sleep diary entries throughout the duration of the programme. The Sleepio programme consists of six sessions, each ranging from five-to twenty minutes in duration. After the first session, each subsequent session is 'unlocked' one week after delivery of the prior session. Accordingly, the programme can be completed within a six-week period. However, the average time taken to complete the programme is 9-10 weeks.

    Treatment: Digital cognitive behavioural therapy for insomnia

  • Control GroupNo study treatment, for comparison

    Participants allocated to the control group will continue to receive 'treatment-as-usual' throughout the duration of the study period. They will be informed that they will be provided with access to the intervention at the end of the study period.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomised Controlled Feasibility Study of a Digital Cognitive Behavioural Therapy for Insomnia Intervention in Mild Cognitive Impairment and Mild Dementia: The Randomised Evaluation of Sleep in Cognitive Impairment Trial
Publications
Record updated
23 January 2026